First Mercantile Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

First Mercantile Trust’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,146	Closed	-$171K	–	954
2019 Q2	$171K	Buy	13,146 +1,624	+14%	+$20.8K	0.02%	493
2019 Q1	$140K	Buy	11,522 +1,265	+12%	+$16.2K	0.03%	574
2018 Q4	$117K	Sell	10,257 -4,769	-32%	-$77K	0.03%	603
2018 Q3	$326K	Buy	15,026 +425	+3%	+$8.89K	0.06%	347
2018 Q2	$258K	Sell	14,601 -404	-3%	-$8.2K	0.05%	428
2018 Q1	$316K	Sell	15,005 -583	-4%	-$11.4K	0.07%	356
2017 Q4	$226K	Buy	15,588 +6,797	+77%	+$105K	0.04%	501
2017 Q3	$139K	Buy	+8,791	New	+$129K	0.03%	643
2017 Q2	–	Sell	-6,350	Closed	-$103K	–	863
2017 Q1	$103K	Sell	6,350 -3,629	-36%	-$52.5K	0.02%	736
2016 Q4	$151K	Buy	9,979 +3,185	+47%	+$45K	0.02%	653
2016 Q3	$104K	Sell	6,794 -906	-12%	-$36.6K	0.01%	719
2016 Q2	$299K	Buy	7,700 +1,586	+26%	+$57K	0.04%	551
2016 Q1	$170K	Sell	6,114 -407	-6%	-$13.6K	0.02%	616
2015 Q4	$351K	Buy	6,521 +3,221	+98%	+$162K	0.04%	537
2015 Q3	$132K	Buy	+3,300	New	+$108K	0.01%	758

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Mercantile Trust's ITCI Position: Q3 2019 in Review

First Mercantile Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2019, closing a stake of 13,146 shares — an estimated $171K sold.

First Mercantile Trust first reported a position in ITCI in Q3 2015 and held it in 15 quarters. The position peaked at $351K in Q4 2015. 126 funds tracked by Wall St. Rank hold ITCI as of Q3 2019.

First Mercantile Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2019 after selling out during the quarter.
First Mercantile Trust sold 13,146 Intra-Cellular Therapies Inc. shares in Q3 2019, an estimated $171K.
First Mercantile Trust first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 15 quarters.
First Mercantile Trust's Intra-Cellular Therapies Inc. position peaked at $351K in Q4 2015.
126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2019.

Based on First Mercantile Trust's 13F filing for Q3 2019, filed 1 Nov 2019.